PTX-100, is a first in class drug that kills cancer cells by blocking geranylgeranyl transferase-1 (GGT-1), a protein required for the cancer-causing activity of  Ral and Rho, that are in turn required for the cancer-causing protein Ras. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors.  Prescient expects to commence Phase 1b/2 clinical trials in breast cancer and multiple myeloma in Q4 2016. At the same time, Prescient plans to develop its novel p27 cancer biomarker as a companion diagnostic that will potentially identify those patients that are most likely to respond to PTX-100 therapy.